When two antigens are better than one
Multispecifics newly into the clinic include Car-Ts from Essen and Unicar.
Conjugates dominate human trial entries
ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
Dizal's US first; now what?
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Regeneron enters the T-cell engager arena
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
M&A analysis: signs of life emerge
Some big deals in the second quarter have raised hopes that takeouts are back.
FDA red and green lights: June 2025
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
